CARTESIAN THERAPEUTICS INC
RNACNASDAQTrading Snapshot
- Day Range
- β
- 52-Week Range
- $5.60 β $11.00
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 30.3M
- Next Earnings
- 2027-03-08
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- β
- P/E Ratio
- β
- P/S Ratio
- 104.3x
- EPS (TTM)
- $-5.87
- Dividend Yield
- β
- Dilution (1yr)
- +0.3%
CARTESIAN THERAPEUTICS INC
RNACAbout CARTESIAN THERAPEUTICS INC
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The companyβs lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates

Bears are Losing Control Over Cartesian Therapeutics, Inc. (RNAC), Here's Why It's a 'Buy' Now
Cartesian Therapeutics, Inc. (RNAC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a tr

Wall Street Analysts See a 379.63% Upside in Cartesian Therapeutics, Inc. (RNAC): Can the Stock Really Move This High?
The consensus price target hints at a 379.6% upside potential for Cartesian Therapeutics, Inc. (RNAC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimat

Cartesian Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) advances towards data readout expected in 1Q27 and biologics license application (BLA) filing planned for mid-2027Β Retreatment data for Descartes-08 in MG s

Cartesian Therapeutics Announces New Employment Inducement Grant
FREDERICK, Md., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the βCompanyβ), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced

Cartesian: Maintaining 'Buy' On Descartes-08 MG Data Release And CAR-T Agreement
Cartesian Therapeutics maintains a 'Buy' rating, driven by advancing Descartes-08 cell therapy programs and imminent late-stage clinical catalysts. Topline results from the phase 3 AURORA study in AChR Ab+ Myasthenia Gra

Cartesian Therapeutics (NASDAQ:RNAC) versus Syndax Pharmaceuticals (NASDAQ:SNDX) Critical Comparison
Syndax Pharmaceuticals (NASDAQ: SNDX - Get Free Report) and Cartesian Therapeutics (NASDAQ: RNAC - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two co